CN109234367A - A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation - Google Patents
A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation Download PDFInfo
- Publication number
- CN109234367A CN109234367A CN201810916683.3A CN201810916683A CN109234367A CN 109234367 A CN109234367 A CN 109234367A CN 201810916683 A CN201810916683 A CN 201810916683A CN 109234367 A CN109234367 A CN 109234367A
- Authority
- CN
- China
- Prior art keywords
- seq
- hepatitis
- resistant mutation
- motif area
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
Abstract
The present invention provides a kind of kits for hepatitis B virus YMDD motif area medicament-resistant mutation, belong to technical field of molecular biology.Specifically use RNase H2 and Taq archaeal dna polymerase two-phase enzyme system, for HBVYMDD drug-tolerant gene mutation rtM204I/V (area C) ± rtL180M (area B) design mode special primer and probe, the detection of hepatitis B virus YMDD motif area medicament-resistant mutation is realized.A possibility that susceptibility of kit provided by the invention is high, and quickly, stability is good, closed detection for detection, reduces Final pollution.
Description
Technical field
The present invention relates to technical field of molecular biology, belong to external diagnosis reagent field medicament-resistant mutation detection method, tool
Body is related to a kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation.
Background technique
Treatment chronic hepatitis B mainly uses interferon or nucleoside analog at present, such as Lamivudine, adefovirdipivoxil, Ganciclovir
Deng interfering hbv replication to achieve the purpose that treatment.Lamivudine (Lamivudine), Chinese name He Puting are that oral karyon is phonetic
Pyridine nucleoside analog was researched and developed successfully and was produced in 1992 by GlaxoSmithKline PLC company, is entered within 1998 China and is gone through to use
In clinic, Lamivudine is convenient to take, adverse reaction is few, easy for patients to accept, is most effective and safe suppression generally acknowledged at present
The nucleosides similar medicine of virus replication processed, the appearance of the medicine make Anti-HBV activity treatment that qualitative leap have occurred, and make to be not suitable for α-interference
Extract for treating or the unresponsive patient for the treatment of have new therapeutic choice.
The duplication of HBV gene group will just can be carried out by reverse transcription mechanism, be initially formed rna replicon intermediate, and rna replicon
The formation of intermediate needs the effect of reverse transcriptase just to be carried out, but the azymia proofreading function, is easy in process of reverse-transcription
Mispairing, which occurs, leads to gene mutation, in HBV gene group the catalyzed combination position of reverse transcriptase polymerase have one it is highly conserved
YMDD motif, i.e. tyrosine-methionine-asparatate-asparatate, Lamivudine can be specifically bound with it,
It is that minus-strand dna and termination DNA chain extension effectively inhibit HBV DNA replication dna by inhibiting pregenome RNA reverse transcription.
YMDD motif is necessary to polymerase activity, is the high conserved region of HBV reverse transcriptase, the HBV after variation is to drawing
The sensibility of meter Fu Ding declines, and so as to cause treatment failure, even results in that sb.'s illness took a turn for the worse.If medicament-resistant mutation continues to use after occurring
Medicine not only increases the unnecessary financial burden of patient and causes the waste of social resources, it is also possible to which there are serious epidemiology
Harm.Clinically whole therapeutic scheme, the rational use of medicines are exchanged in the variation of detection YMDD motif and improving curative effect, there is important guidance to anticipate
Justice.
The medicament-resistant mutation generated during Lomivudine on Hepatitis B is reported in recent years is concentrated mainly on 552 amino acids
YMDD → YIDD/YVDD, i.e., base occurs in HBVYMDD motif area and substitutes G743T or A741G, is i.e. Atg → Att/Gtg has
Interest is in addition to these base mutations are also often accompanied by other base mutations in some medicament-resistant mutations, as M552V mutation is always accompanied by P
The L528M in the area gene B is mutated, and two kinds of mutation exist simultaneously may be related with M552V and M552I drug resistance power.Experiment in vitro
Show the strong and weak sequence of various mutant drug-resistants are as follows: M552I > L528M+M552V > M552V > L528M, it at present it has been proposed that will
These mutation are divided into I group (M552V/L528M) and II group (M552I).
According to new nomenclature, the variable position and type of the relevant HBV persister of Lamivudine are rtM204I/V (C
Area) ± rtL180M (area B), experiment in vitro shows that rtL180M can not only restore the duplication energy of C region mutation strain (rtM204I/V)
Power, and the tolerance degree to nucleoside analogue drugs can be increased.Two kinds of mutation combinations are prompted to occur more prominent than single form
Become the drug resistance that may more increase virus.
The detection method of medicament-resistant mutation is mainly include the following types: mass spectral analysis, fluorescence polarization, PCR- peptide nucleic acid, limit at present
Property fragment length polymorphic method RFLP processed, Line probe assay method LiPA, quantitative fluorescent PCR melting curve analysis method, PCR are reversed
Dot hybridization.Mass spectral analysis, fluorescence polarization are very high or cumbersome to technology and equipment requirement, are unfavorable for vast basic hospital
Carry out application.
The advantages of fluorescent PCR is to be quick on the draw, is specific high: with the special Taqman probe of template sequence in primer spy
The specificity of the PCR further increased on the basis of different；One specific product of every amplification only discharges the fluorescent dye of a molecule,
Instrument detection is specific amplified as a result, non-specific product does not influence detection signal, effectively improves the specificity of detection.
There are many fluorophors of different wave length to available so that Taqman sonde method may be implemented to detect in same pipe it is multiple
PCR reduces cost and also improves efficiency avoiding the influence that fluorescent dye reacts PCR with accuracy.
RNase H2 is a kind of enzyme of single-minded identification RNA-DNA heterozygote, and can specific recognition single rna base and DNA
The site of template complementation.This patent is combined using RNase H2 and round pcr develops a kind of novel hepatitis type B virus
YMDD motif area medicament-resistant mutation detection method does not inquire temporarily at present this method applying to hepatitis B virus YMDD motif area
The relevant technologies in medicament-resistant mutation detection.
Summary of the invention
In view of this, the present invention takes full advantage of the advantages of Taqman probe technique, in conjunction with the characteristics of RNase H2, use
Double enzyme systems are directed to HBV YMDD drug-tolerant gene mutation rtM204I/V (area C) ± rtL180M (area B) design mode specific probe, respectively
Probe marks different fluorescent dyes, detects in different wave length, to achieve the purpose that the low Resistance mutation gene of detection, the present invention
A kind of hepatitis B virus YMDD motif area medicament-resistant mutation detection kit provided sensitiveer easily can carry out sample
Detection.
First aspect present invention provides one group of primer sets for being directed to hepatitis B virus YMDD motif area medicament-resistant mutation, institute
Stating primer combination includes: specific primer sequence SEQ ID NO.1 and SEQ the ID NO.2 for detecting the mutational site rtM204I, inspection
Specific primer sequence SEQ ID NO.1 and SEQ the ID NO.3 in the mutational site rtM204V is surveyed, the mutational site rtL180M is detected
Specific primer sequence SEQ ID NO.4 and SEQ ID NO.5.Wherein, W is A+T degeneracy base, and lowercase a, c are represented
Ribonucleic acid base, capitalization represent DNA base, the primer sequence SEQ ID NO.2, SEQ ID
NO.3, SEQ ID NO.4 the end 3' be connected with spacerarm x.Above-mentioned primer can specifically in conjunction with template sequence, and
It can specific amplified after RNase H2 shearing.
Second aspect of the present invention provides a kind of probe for hepatitis B virus YMDD motif area medicament-resistant mutation, the spy
Needle is located at one section of oligonucleotides single stranded sequence in respective target nucleic acid sequence region, can specifically with target nucleic acid sequence base
Pairing, the probe includes: probe sequence SEQ ID NO.6 corresponding for the mutational site rtM204I/V, is needed and primer
SEQ ID NO.1~SEQ ID NO.3 is used together；For the corresponding probe sequence SEQ ID in the mutational site rtL180M
NO.7 needs to be used together with primer SEQ ID NO.4 with SEQ ID NO.5.Wherein, Y is C+T degeneracy base, sequence SEQ
5 ' the ends of ID NO.6 and SEQ ID NO.7 are marked with fluorophor, and 3 ' ends are marked with quenching group.
Preferably, the end of SEQ ID NO.6 probe 5 ' is marked with FAM fluorophor, and 3 ' ends are marked with quenching group
BHQ1；The end of SEQ ID NO.7 probe 5 ' is marked with FAM fluorophor, and 3 ' ends are marked with quenching group BHQ1.
Third aspect present invention provides a kind of enzyme mixation for hepatitis B virus YMDD motif area medicament-resistant mutation,
Including RNase H2 and thermal starting Taq archaeal dna polymerase, the RNase H2 enzyme and Taq archaeal dna polymerase concentration ratio be 1:50~
1:500。
Fourth aspect present invention provides a kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation, packet
Include above-mentioned specific primer sequence SEQ ID NO.1~SEQ ID NO.5, above-mentioned probe sequence SEQ ID NO.6 and SEQ ID
NO.7, above-mentioned enzyme mixation, PCR buffer, 4 kinds of dNTPs.
Preferably, the kit for hepatitis B virus YMDD motif area medicament-resistant mutation is made of following reagent:
(1) PCR reaction premixed liquid 1: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.6, primer by
SEQ ID NO.1 and SEQ ID NO.2 is mixed；
(2) PCR reaction premixed liquid 2: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.6, primer by
SEQ ID NO.1 and SEQ ID NO.3 is mixed；
(3) PCR reaction premixed liquid 3: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.7, primer by
SEQ ID NO.4 and SEQ ID NO.5 is mixed；
(4) enzyme mixation: main component is mixed by RNase H2 and thermal starting Taq archaeal dna polymerase, the RNase
H2 enzyme and Taq archaeal dna polymerase concentration ratio are 1:50~1:500；
(5) negative quality-control product: the normal human serum of the YMDD mutation feminine gender by inactivation treatment；
(6) positive quality control product: the human serum of the YMDD rtM204I+rtL180M mutation positive by inactivation treatment.
More preferred, in the enzyme mixation, RNase H2 enzyme and Taq archaeal dna polymerase concentration ratio are 1:250.
More preferred, reagent further includes DNA extracting solution in the kit.The DNA extracting solution is used for from B-mode liver
Scorching serum virus sample carries out DNA extracting, is extracted as conventional hepatitis type B virus concentration cleavage method.But the extraction side of DNA
Formula is not limited to using this DNA extracting solution, and the DNA concentration lytic reagent box that also may be selected to use other conventional obtains DNA and makees
For template.
The beneficial effects of the present invention are: the present invention develop it is a kind of new for hepatitis B virus YMDD motif area drug resistance
The kit of abrupt climatic change has used two-phase enzyme system RNase H2 and archaeal dna polymerase technology, due to using double enzyme systems
Amplification changes on the basis of general primer, i.e., is made with a RNA base instead of DNA base at the end 3' of primer
RNase H2 can play a role, and devise the primed probe for the mutational site rtM204I/V, the mutational site rtL180M, adopt
With fluorescent PCR, closed detection, a possibility that reducing Final pollution, in addition, comparing PCR revert dot blot hybridization, detection time
It can be shortened half, efficiency significantly improves.
Detailed description of the invention
Fig. 1 show the amplification curve of the mutational site the rtM204I positive；
Fig. 2 show the amplification curve of the mutational site the rtM204V positive；
Fig. 3 show the amplification curve of the mutational site the rtL180M positive；
Fig. 4 show sample rtM204V mutation, rtL180M sports positive amplification curve.
Specific embodiment
Below in conjunction with specific embodiment to provided by the invention a kind of for hepatitis B virus YMDD motif area drug resistance
The kit of mutation is further described.The embodiments described below is exemplary, for explaining only the invention, and cannot
It is interpreted as limitation of the present invention.
Experimental method in following embodiments is unless otherwise specified conventional method.Reality as used in the following examples
It tests material unless otherwise specified, is that market is commercially available.
Embodiment one
The present embodiment devises the primed probe for hepatitis B virus YMDD motif area medicament-resistant mutation, and design is directed to
Specific primer SEQ ID NO.1 and SEQ the ID NO.2 in the mutational site rtM204I, for the special of the mutational site rtM204V
The property corresponding probe SEQ ID NO.6 in the mutational site primer SEQ ID NO.1 and SEQ ID NO.3 and rtM204I/V；For
Specific primer SEQ ID NO.4 and SEQ the ID NO.5 in the mutational site rtL180M, and it is corresponding for the mutational site rtL180M
Probe SEQ ID NO.7.Particular sequence is as follows:
5'-AGTCCGTTTCTCTTGGCTC-3, sequence is as shown in SEQ ID NO.1；
5'-CCCCAAWACCACATCATCaAAATA-x, sequence is as shown in SEQ ID NO.2；
5'-CCAAWACCACATCATCCAcATAAC-x, sequence is as shown in SEQ ID NO.3；
5'-GGCCTCAGTCCGTTTCTCaTGG-x, sequence is as shown in SEQ ID NO.4；
5'-AGCGGCATAAAGGGACTC-3', sequence is as shown in SEQ ID NO.5；
FAM-GGGAAAGCCCTACGAACCACTG-BHQ1, sequence is as shown in SEQ ID NO.6；
FAM-TGCCATTTGTTCAGTGGTTCGYAGG-BHQ1, sequence is as shown in SEQ ID NO.7.
Above-mentioned primer is unlike general primer, and the invention patent is due to using double enzyme system amplification, i.e.,
Therefore the double enzyme systems of RNase H2 and Taq archaeal dna polymerase change on the basis of general primer, i.e., in the 3' of primer
Hold a RNA base instead of DNA base, such RNase H2 competence exertion effect.The invention patent is by dividing sequence
The optimization design of analysis and primed probe, finishing screen have selected and can be mutated to for rtM204I for one group shown in the invention patent
The primed probe in site, the mutational site rtM204V, the mutational site rtL180M.In order to guarantee the reliability of detection system, this hair
Bright patent also introduces positive and negative quality-control product.
Embodiment two
The present embodiment is prepared for a kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation.
Kit specifically designs as follows:
(1) DNA extracting solution, including concentrate and lysis buffer；
(2) PCR reaction premixed liquid 1: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.6, primer by
SEQ ID NO.1 and SEQ ID NO.2 is mixed；Wherein, probe SEQ ID NO.6 concentration is 0.25 μM, primer SEQ ID
NO.1 and SEQ ID NO.2 concentration is 0.25 μM.
(3) PCR reaction premixed liquid 2: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.6, primer by
SEQ ID NO.1 and SEQ ID NO.3 is mixed；Wherein, probe SEQ ID NO.6 concentration is 0.25 μM, primer SEQ ID
NO.1 and SEQ ID NO.3 concentration is 0.25 μM.
(5) PCR reaction premixed liquid 3: main component have PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.7, primer by
SEQ ID NO.4 and SEQ ID NO.5 is mixed；Wherein, probe SEQ ID NO.7 concentration is 0.25 μM, primer SEQ ID
NO.4 and SEQ ID NO.5 concentration is 0.25 μM.
(6) enzyme mixation: main component is mixed by RNase H2 and thermal starting Taq archaeal dna polymerase, the RNase
H2 enzyme and Taq archaeal dna polymerase concentration ratio are 1:250；The Taq archaeal dna polymerase concentration is 0.5U.
(7) negative quality-control product: the normal human serum of the YMDD mutation feminine gender by inactivation treatment；
(8) positive quality control product: the human serum of the YMDD rtM204I+rtL180M mutation positive by inactivation treatment.
Different size of kit is packaged into according to different size by above-mentioned eight kinds of reagents.
Embodiment three
The examination for hepatitis B virus YMDD motif area medicament-resistant mutation that the present embodiment uses embodiment two to be prepared
Agent box detects sample, and specific detecting step is as follows.
(1) it extracts HBV DNA profiling: the HBV DNA mould in hepatitis type B virus serum sample is extracted using DNA extracting solution
Plate.
Detailed process includes: concentrate 100 μ L, 12000rpm to be added into hepatitis type B virus serum centrifugation 10 minutes；
Abandon supernatant；The mixing of 25 μ L lysis buffers is added, 100 DEG C crack for 10 minutes；Last 12000rpm is centrifuged 10 minutes, and supernatant is
HBVDNA template used.
(2) PCR amplification detect: using step (1) extract HBV DNA as template, using kit provided by the invention into
The corresponding augmentation detection of row.
PCR reaction premixed liquid 1,2 and 3 is made into mixed liquor 1, mixed liquor according to 36:0.5 mass ratio with enzyme mixation respectively
2, after mixed liquor 3,36 μ L mixed liquors 1,36 μ L mixed liquors 2,36 μ L mixed liquors 3 is added in corresponding reacting hole, are then divided
The 4 μ l of HBV DNA profiling of extraction is not added, establishes 40 μ L PCR reaction systems and carries out PCR reaction, while doing a negative control
Hole and a Positive control wells.PCR reaction condition be 95 DEG C initial denaturation 5 minutes, be then denaturalized 10 seconds for 95 DEG C, 60 DEG C of annealing extensions
45 seconds, totally 35 circulation, collected fluorescence in the annealing extension stage.
(3) result judgement: according to the signal value of each fluorescence channel to determine whether there is amplification, amplification just represents the fluorescence
The corresponding detection site in channel is that the positive does not expand that is, with the presence of mutation, just illustrates the corresponding detection site mutation in the channel
It detects and limits lower than this kit.
The mutational site the rtM204I positive sample that measures according to the above method, the mutational site rtM204V positive sample,
The amplification curve of the mutational site rtL180M positive sample is respectively as shown in attached drawing 1~3.
By for the detection of kit Mr. Yu's serum sample of hepatitis B virus YMDD motif area medicament-resistant mutation, use
DNA extracting solution extracts the HBV DNA profiling in serum sample, and step is detected according to the above method, detection gained amplification curve
As shown in Fig. 4, Fig. 4 shows that sample rtM204V sports the positive, and rtL180M sports the positive, kit test result with
Sequencing result is consistent.
Further, the serum sample for choosing 100 HBV patients carries out hepatitis B virus YMDD base using kit
The test of sequence area medicament-resistant mutation, the kit test result of above-mentioned clinical sample is compareed with sequencing result, match rate up to 98.3%,
Clinical sample verification result is good.Kit provided by the invention and detection method can fast and accurately be directed to hepatitis B
Virus YMDD motif area medicament-resistant mutation is detected, and accuracy in detection and detection efficiency are high, for clinically hepatitis B patient reality
When adjustment therapeutic scheme, the rational use of medicines and improve curative effect have important directive significance.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, it is all in spirit of the invention and
Within principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (9)
1. a kind of primer sets for hepatitis B virus YMDD motif area medicament-resistant mutation, it is characterised in that: the primer combination
Include: specific primer sequence SEQ ID NO.1 and SEQ the ID NO.2 for detecting the mutational site rtM204I, detects rtM204V
Specific primer sequence SEQ ID NO.1 and SEQ the ID NO.3 in mutational site detects the specificity in the mutational site rtL180M
Primer sequence SEQ ID NO.4 and SEQ ID NO.5.
2. a kind of probe for hepatitis B virus YMDD motif area medicament-resistant mutation, it is characterised in that: the probe includes: needle
Probe sequence SEQ ID NO.6 corresponding to the mutational site rtM204I/V, for the corresponding probe sequence in the mutational site rtL180M
SEQ ID NO.7 is arranged, the 5 ' ends of the sequence SEQ ID NO.6 and SEQ ID NO.7 are marked with fluorophor, and 3 ' ends are marked with
Quenching group.
3. a kind of enzyme mixation for hepatitis B virus YMDD motif area medicament-resistant mutation, it is characterised in that: including RNase
H2 and thermal starting Taq archaeal dna polymerase, the RNase H2 enzyme and Taq archaeal dna polymerase concentration ratio are 1:50~1:500.
4. a kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation, it is characterised in that: including claim 1
Specific primer sequence SEQ ID NO.1~SEQ ID NO.5, probe sequence SEQ ID NO.6 described in claim 2 and
SEQ ID NO.7, enzyme mixation described in claim 3, PCR buffer, dNTPs.
5. being directed to the kit of hepatitis B virus YMDD motif area medicament-resistant mutation as claimed in claim 4, it is characterised in that:
Including following reagent:
(1) PCR reaction premixed liquid 1: main component include: PCR buffer, 4 kinds of dNTPs, SEQ ID NO.6, by SEQ ID
The primer sets that NO.1 and SEQ ID NO.2 is mixed；
(2) PCR reaction premixed liquid 2: main component include: PCR buffer, 4 kinds of dNTPs, SEQ ID NO.6, by SEQ ID
The primer sets that NO.1 and SEQ ID NO.3 is mixed；
(3) PCR reaction premixed liquid 3: main component has PCR buffer, 4 kinds of dNTPs, probe SEQ ID NO.7, primer by SEQ
ID NO.4 and SEQ ID NO.5 is mixed；
(4) enzyme mixation: main component includes: RNase H2 and thermal starting Taq archaeal dna polymerase, the RNase H2 enzyme with
Taq archaeal dna polymerase concentration ratio is 1:50~1:500；
(5) negative quality-control product: for the negative normal human serum of the YMDD mutation Jing Guo inactivation treatment；
(6) positive quality control product: for the positive human serum of the YMDD rtM204I+rtL180M mutation Jing Guo inactivation treatment.
6. being directed to the kit of hepatitis B virus YMDD motif area medicament-resistant mutation as claimed in claim 5, it is characterised in that:
In the enzyme mixation, RNase H2 enzyme and Taq archaeal dna polymerase concentration ratio are 1:250.
7. being directed to the kit of hepatitis B virus YMDD motif area medicament-resistant mutation as claimed in claim 5, it is characterised in that:
5 ' the ends of the probe sequence SEQ ID NO.6 and SEQ ID NO.7 are marked with FAM fluorophor, and 3 ' ends, which are marked with, is quenched base
Group BHQ1.
8. being directed to the kit of hepatitis B virus YMDD motif area medicament-resistant mutation as claimed in claim 5, it is characterised in that:
The primer sequence SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 the end 3' be connected with spacerarm.
9. being directed to the kit of hepatitis B virus YMDD motif area medicament-resistant mutation as claimed in claim 5, it is characterised in that:
Reagent further includes DNA extracting solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810916683.3A CN109234367A (en) | 2018-08-13 | 2018-08-13 | A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810916683.3A CN109234367A (en) | 2018-08-13 | 2018-08-13 | A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109234367A true CN109234367A (en) | 2019-01-18 |
Family
ID=65070325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810916683.3A Pending CN109234367A (en) | 2018-08-13 | 2018-08-13 | A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109234367A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109161588A (en) * | 2018-09-29 | 2019-01-08 | 武汉千麦医学检验所有限公司 | For detecting primer sets, probe, kit and the detection method of hepatitis B virus YMDD motif area medicament-resistant mutation |
| CN110656204A (en) * | 2019-11-14 | 2020-01-07 | 郑州安图生物工程股份有限公司 | Hepatitis B virus YMDD gene mutation detection kit and detection method |
| CN115074424A (en) * | 2022-08-19 | 2022-09-20 | 深圳市芯思微生物科技有限公司 | PCR reaction solution and aerosol pollution prevention PCR amplification method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1737164A (en) * | 2004-08-27 | 2006-02-22 | 上海复旦悦达生物技术有限公司 | Method for quickly detecting hepatitis B virus drug-resistant gene variation |
| CN108148895A (en) * | 2017-12-29 | 2018-06-12 | 星阵（广州）基因科技有限公司 | For detecting primer, kit and the method for people's AKT1 genes of mutation |
| CN108291253A (en) * | 2015-11-25 | 2018-07-17 | 综合基因技术公司 | Method for variant detection |
-
2018
- 2018-08-13 CN CN201810916683.3A patent/CN109234367A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1737164A (en) * | 2004-08-27 | 2006-02-22 | 上海复旦悦达生物技术有限公司 | Method for quickly detecting hepatitis B virus drug-resistant gene variation |
| CN108291253A (en) * | 2015-11-25 | 2018-07-17 | 综合基因技术公司 | Method for variant detection |
| CN108148895A (en) * | 2017-12-29 | 2018-06-12 | 星阵（广州）基因科技有限公司 | For detecting primer, kit and the method for people's AKT1 genes of mutation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109161588A (en) * | 2018-09-29 | 2019-01-08 | 武汉千麦医学检验所有限公司 | For detecting primer sets, probe, kit and the detection method of hepatitis B virus YMDD motif area medicament-resistant mutation |
| CN110656204A (en) * | 2019-11-14 | 2020-01-07 | 郑州安图生物工程股份有限公司 | Hepatitis B virus YMDD gene mutation detection kit and detection method |
| CN115074424A (en) * | 2022-08-19 | 2022-09-20 | 深圳市芯思微生物科技有限公司 | PCR reaction solution and aerosol pollution prevention PCR amplification method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3339451B1 (en) | Primers for detecting influenza by using lamp, and use thereof | |
| CN103710460B (en) | Test kit of detection by quantitative EGFR genetic mutation and uses thereof | |
| Liang et al. | Rapid detection and tracking of Omicron variant of SARS-CoV-2 using CRISPR-Cas12a-based assay | |
| US20180073087A1 (en) | Qualitative and absolute quantification kit for detecting hepatitis b virus cccdna | |
| JP6619332B2 (en) | Methods and compositions for detecting mutations in the human EZH2 gene | |
| CN111394431B (en) | Method for detecting nucleic acid by using double real-time fluorescent isothermal amplification technology | |
| CN109234367A (en) | A kind of kit for hepatitis B virus YMDD motif area medicament-resistant mutation | |
| EP2258878A1 (en) | A method for detecting HBV using real time PCR | |
| EP2808387B1 (en) | Oligonucleotide for hiv detection, hiv detection kit, and hiv detection method | |
| WO2023279042A2 (en) | Compositions and methods for detection of severe acute respiratory syndrome coronavirus 2 variants | |
| CN101182585A (en) | Method for identifying HBV gene mutation type, special chip and reagent kit | |
| CN103103259A (en) | Method, kit and primers for determining whether two predetermined loci of nucleic acid sample mutate or not | |
| CN109234368A (en) | A method of for hepatitis B virus YMDD motif area medicament-resistant mutation | |
| WO2021180337A1 (en) | Molecular fingerprinting methods to detect and genotype different rna targets through reverse transcription polymerase chain reaction in a single reaction | |
| CN109161588A (en) | For detecting primer sets, probe, kit and the detection method of hepatitis B virus YMDD motif area medicament-resistant mutation | |
| CN116769939A (en) | Primer combination for detecting fluoroquinolone drug-resistant mutation of mycobacterium tuberculosis | |
| CN110894546A (en) | RAA constant temperature fluorescence detection method and reagent for fish viral nervous necrosis disease virus (VNNV) | |
| CN109355433A (en) | A kind of very fast fluorescence PCR detection reagent kit of Hantaan virus and its primer combination of probe | |
| KR102435116B1 (en) | Method for detecting influenza virus using CRISPR-Cas system and multiplex LAMP primer set | |
| Moser et al. | Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1 | |
| US11976338B2 (en) | Method of manufacturing coronavirus diagnostic kit, virus diagnostic kit manufactured thereby and method of diagnosing coronavirus using the same | |
| CN111500768B (en) | Primer probe for identifying novel coronavirus and application of primer probe in dual-digital PCR | |
| JP2023552693A (en) | System for detecting target gene mutations and viral genomes, and methods for producing and using the same | |
| CN107034312A (en) | Polynucleotide composition, kit and application thereof | |
| US8258283B2 (en) | Method for detection of HCV at the real time PCR with intercalating dye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |
|
| RJ01 | Rejection of invention patent application after publication |